# Antazoline in Rapid Cardioversion of Paroxysmal Atrial Fibrillation

> **NCT01527279** · PHASE4 · COMPLETED · sponsor: **National Institute of Cardiology, Warsaw, Poland** · enrollment: 74 (actual)

## Conditions studied

- Paroxysmal Atrial Fibrillation

## Interventions

- **DRUG:** antazoline
- **DRUG:** 0.9% saline

## Key facts

- **NCT ID:** NCT01527279
- **Lead sponsor:** National Institute of Cardiology, Warsaw, Poland
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2012-11
- **Primary completion:** 2015-01
- **Final completion:** 2015-03
- **Target enrollment:** 74 (ACTUAL)
- **Last updated:** 2015-05-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01527279

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01527279, "Antazoline in Rapid Cardioversion of Paroxysmal Atrial Fibrillation". Retrieved via AI Analytics 2026-09-26 from https://api.ai-analytics.org/clinical/NCT01527279. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*